GlassScriptPhysician profile
Rubin Chandran
NPI 1972571024
$6,294.07
in general payments reported to CMS, 2019-2025
22 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,619 · 2020: $30.96 · 2021: $50.04 · 2022: $372 · 2023: $93.28 · 2024: $745 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.51 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $4,694.71 | 2019-2022 | |
| Outset Medical INC | $462.75 | 2024-2025 | |
| Amgen INC. | $221.12 | 2020-2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $174.39 | 2021-2025 | |
| Nxstage Medical, INC. | $107.01 | 2019 | |
| Mallinckrodt Hospital Products INC. | $94.83 | 2023-2025 | Terlivaz, Acthar |
| Akebia Therapeutics INC | $67.33 | 2019-2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $46.55 | 2024-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $46.08 | 2023-2024 | Benlysta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $43.63 | 2024 | |
| Travere Therapeutics, INC. | $43.37 | 2021-2024 | |
| Scpharmaceuticals INC. | $43.23 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $40.05 | 2022-2024 | Jynarque |
| Horizon Therapeutics Plc | $37.41 | 2022-2023 | Krystexxa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $21.00 | 2022 | |
| Calliditas Therapeutics US INC. | $19.25 | 2024 | |
| Edwards Lifesciences Corporation | $19.20 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $18.31 | 2024 | Farxiga |
| Daiichi Sankyo INC. | $17.65 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.82 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $15.01 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubin Chandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.